Huntington's Disease Treatment
For Huntington's disease, initiate symptomatic management with tetrabenazine, deutetrabenazine (Austedo), or valbenazine (Ingrezza) as first-line agents for chorea, while simultaneously addressing psychiatric and cognitive symptoms with targeted antipsychotics and antidepressants, recognizing that no disease-modifying therapy currently exists despite promising gene therapy trials. 1
Current Treatment Framework
Motor Symptom Management (Chorea)
The FDA-approved vesicular monoamine transporter 2 (VMAT2) inhibitors form the cornerstone of chorea management 1:
- Tetrabenazine: First-line option with established efficacy
- Deutetrabenazine (Austedo): Improved pharmacokinetic profile
- Valbenazine (Ingrezza): Alternative VMAT2 inhibitor
In German-speaking countries, tiapride is preferred over tetrabenazine in clinical practice 2. For severe chorea unresponsive to monotherapy, combining a postsynaptic antidopaminergic agent (tiapride) with a presynaptic agent (tetrabenazine) may provide additive benefit 2.
Psychiatric and Behavioral Management
Antipsychotics serve dual purposes—managing both psychiatric symptoms and chorea 1, 2:
- Haloperidol: Effective for chorea and psychosis
- Risperidone: Particularly useful for irritability, with additional chorea benefit and sleep improvement
- Olanzapine: Addresses weight loss (common in HD), chorea, and psychiatric symptoms
- Quetiapine: Functions as mood stabilizer with antidepressant properties
- Sulpiride: Alternative antipsychotic option
Dose timing strategy: Administer highest daily doses at night to leverage sedative effects for sleep improvement 2.
Critical Treatment Principles
Individualized polypharmacy is necessary because HD patients simultaneously experience motor, psychiatric, and cognitive symptoms that require multi-domain treatment 2. When new symptoms emerge during treatment, always consider medication side effects as a potential cause before adding additional agents 2.
Disease-Modifying Therapies: Current Status
Gene Therapy Developments
While multiple approaches targeting mutant huntingtin (mHTT) reduction are under investigation, none have achieved regulatory approval 1:
Tominersen (antisense oligonucleotide): The phase III GENERATION HD1 trial was halted in March 2021 after showing faster neurologic decline in the high-dose group compared to placebo 1. Post-hoc analyses suggested potential benefit in younger patients with lower disease burden, but this remains unproven 1.
Mechanisms under investigation 1:
- Antisense oligonucleotides (ASOs)
- RNA interference (RNAi)
- CRISPR-Cas9 gene editing
- Small molecule splicing modulators
Why Gene Therapies Have Failed
The Tominersen failure highlights critical challenges 1:
- Inadequate drug penetration to basal ganglia (key affected region)
- Non-selective reduction of both wild-type and mutant huntingtin
- Potential neurotoxicity from localized high concentrations after intrathecal injection
- Early elevation of neurofilament light (NfL) indicating neuronal damage
Evidence Quality and Guideline Gaps
The evidence base for HD treatment remains limited 3, 4. Most recommendations derive from expert consensus rather than high-quality randomized controlled trials. The 2019 international guidelines used a formalized consensus method when evidence was insufficient 3, and the 2024 Korean evidence-based review emphasized the need for more robust clinical trials 4.
Missing guidelines exist for 5:
- General practitioners
- Nurses
- Psychologists
- Social workers
- Case managers/care coordinators
Practical Management Algorithm
Establish treatment priorities by clearly delineating target symptoms (chorea vs. dystonia vs. bradykinesia vs. psychiatric symptoms) 2
For predominant chorea: Start VMAT2 inhibitor (tetrabenazine, deutetrabenazine, or valbenazine) 1
For combined chorea + psychiatric symptoms: Consider risperidone or olanzapine for synergistic effects 2
For severe refractory chorea: Combine postsynaptic (tiapride) + presynaptic (tetrabenazine) antidopaminergic agents 2
For weight loss: Prioritize olanzapine 2
For mood instability: Use quetiapine 2
Monitor for medication side effects when new symptoms emerge rather than reflexively adding agents 2
Common Pitfalls
- Assuming all movement disorders are chorea: HD presents with myoclonus, dystonia, bradykinesia, and Parkinsonism requiring different approaches 2
- Overlooking medication interactions: Polypharmacy increases risk of adverse effects and drug-drug interactions 1
- Premature gene therapy expectations: Despite promising preclinical data, no gene therapy has demonstrated clinical benefit in phase III trials 1
- Neglecting non-motor symptoms: Cognitive decline and psychiatric symptoms significantly impact quality of life and require equal attention 4
Future Directions
Multidisciplinary care networks with central care coordination are essential 5, though formal guidelines for this structure remain undeveloped. The field is moving toward multi-target/functional drugs that address multiple pathogenic mechanisms simultaneously 6, and biomarker-driven strategies for earlier diagnosis and treatment monitoring 7.